Hyperbaric Oxygenation May Increase Lung Injury
Hyperbaric Oxygenation May Increase Lung Injury
批准号:
7034016
负责人:
Michail Sitkovsky
金额:
$19.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-01 至 2008-04-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Hyperbaric Oxygen therapy (HBOT) is of interest to basic biomedical researchers and to practitioners of complementary and alternative medicine (CAM). HBOT is applied to a wide variety of diseases with symptoms caused by a lack of oxygen in the target tissues. It is not accepted as a treatment by the US medical community due to the lack of understanding of the underlying physiology and yet to be carefully evaluated potential dangers. Extensive pre-clinical studies are required to overcome the current bias towards HBOT and to determine its limitations. The central goal of this proposal is to understand the mechanisms of beneficial effects of HBOT and to identify its potential dangers. We recently established the critical role of the hypoxia-driven and A2A and A2B adenosine receptor (A2AR/A2BR)-mediated pathway in inhibition of overactive inflammatory cells and protection of normal tissues in hypoxic inflamed areas. We hypothesize that the elimination of this mechanism by oxygen during HBOT may explain the beneficial effects of HBOT in clearing infections by "de-inhibited" immunocytes. We are also concerned that the weakening of this protective mechanism by HBOT may lead to an unintended exacerbation of inflammatory tissue damage. We plan to test our hypothesis in studies of HBOT-treated wild type mice and of unique mice with total and tissue-specific deletion of A2AR and/or A2BR genes in different models of lung inflammation. Our specific aims #1 and 2 are to test whether HBOT exacerbates lung inflammation in studies of inhalative and intravenously induced models of lung injury in mice, while in Aim #3 we will test whether compensatory treatment with A2AR agonist will prevent the inflammatory lung injury exacerbation by HBOT in order to gain potential benefits of HBOT for other indications in CAM and other therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preventing the Hypoxia-Adenosinergic Inhibtion of Anti-HIV Immune Response
-
批准号:8043237
-
项目类别:
-
资助金额:$28.45万
-
财政年份:2010
-
负责人:Michail Sitkovsky
-
依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
-
批准号:7100600
-
项目类别:
-
资助金额:$22.29万
-
财政年份:2006
-
负责人:Michail Sitkovsky
-
依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
-
批准号:7409103
-
项目类别:
-
资助金额:$21.65万
-
财政年份:2006
-
负责人:Michail Sitkovsky
-
依托单位:
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
-
批准号:8464014
-
项目类别:
-
资助金额:$20.15万
-
财政年份:2006
-
负责人:Michail Sitkovsky
-
依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
-
批准号:7787425
-
项目类别:
-
资助金额:$21.65万
-
财政年份:2006
-
负责人:Michail Sitkovsky
-
依托单位:
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
-
批准号:9068777
-
项目类别:
-
资助金额:$21.44万
-
财政年份:2006
-
负责人:Michail Sitkovsky
-
依托单位:
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
-
批准号:8826036
-
项目类别:
-
资助金额:$21.44万
-
财政年份:2006
-
负责人:Michail Sitkovsky
-
依托单位:
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
-
批准号:8640889
-
项目类别:
-
资助金额:$20.8万
-
财政年份:2006
-
负责人:Michail Sitkovsky
-
依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
-
批准号:7236729
-
项目类别:
-
资助金额:$21.65万
-
财政年份:2006
-
负责人:Michail Sitkovsky
-
依托单位:
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
-
批准号:8237886
-
项目类别:
-
资助金额:$21.44万
-
财政年份:2006
-
负责人:Michail Sitkovsky
-
依托单位:
Hyperbaric Oxygenation May Increase Lung Injury
-
批准号:7229973
-
项目类别:
-
资助金额:$19.06万
-
财政年份:2006
-
负责人:Michail Sitkovsky
-
依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
-
批准号:7596426
-
项目类别:
-
资助金额:$21.65万
-
财政年份:2006
-
负责人:Michail Sitkovsky
-
依托单位:
Mechanisms of Tumor Protection for T Cells by Hypoxia
-
批准号:7369892
-
项目类别:
-
资助金额:$29.4万
-
财政年份:2005
-
负责人:Michail Sitkovsky
-
依托单位:
Mechanisms of Tumor Protection for T Cells by Hypoxia
-
批准号:7026014
-
项目类别:
-
资助金额:$30.28万
-
财政年份:2005
-
负责人:Michail Sitkovsky
-
依托单位:
Mechanisms of Tumor Protection for T Cells by Hypoxia
-
批准号:7196484
-
项目类别:
-
资助金额:$29.4万
-
财政年份:2005
-
负责人:Michail Sitkovsky
-
依托单位:
Mechanisms of Tumor Protection for T Cells by Hypoxia
-
批准号:6868595
-
项目类别:
-
资助金额:$31.03万
-
财政年份:2005
-
负责人:Michail Sitkovsky
-
依托单位:
Mechanisms of Tumor Protection for T Cells by Hypoxia
-
批准号:7563319
-
项目类别:
-
资助金额:$29.4万
-
财政年份:2005
-
负责人:Michail Sitkovsky
-
依托单位:
BIOCHEMICAL MODULATION OF IMMUNE RESPONSE IN VIVO AND IN VITRO
-
批准号:6098991
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Michail Sitkovsky
-
依托单位:
BIOCHEMICAL MODULATION OF IMMUNE RESPONSE IN VIVO AND IN VITRO
-
批准号:6288898
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Michail Sitkovsky
-
依托单位:
Molecular/Cellular Mechanisms- Immunodeficiency ADA SCID
-
批准号:6506904
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Michail Sitkovsky
-
依托单位:
国内基金
海外基金
登录
查看更多内容
缺氧诱导因子(HIF)-2α转录抑制树突状细胞CD36表达减轻肾脏缺血再灌注损伤的机制
-
批准号:82370751
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:张明
-
依托单位:
靶向纳米颗粒调控HIF-1α通路抑制缺氧三阴性乳腺癌耐药和转移的研究
-
批准号:31900567
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:田浩
-
依托单位:
Egr-1调控低氧下细胞自噬引起肝癌化疗抵抗的机制研究
-
批准号:31100964
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2011
-
负责人:彭琬昕
-
依托单位:
肝刺激因子HSS对肝脏缺血-再灌注损伤的保护作用及机制
-
批准号:81100310
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:李文
-
依托单位:
肝血窦内皮细胞AOC3基因在重症休克-复苏过程中的功能与调控机制
-
批准号:81101419
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:姚骏
-
依托单位:
气体信号分子硫化氢对腰椎间盘髓核细胞凋亡影响的实验研究
-
批准号:81071504
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:李淳德
-
依托单位:
内源性二氧化硫对低氧性肺血管基质重塑的调节作用及机制
-
批准号:81070111
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:杜军保
-
依托单位:
肝癌细胞乏氧微环境下kit配基的表达调控机制及其功能研究
-
批准号:30901448
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2009
-
负责人:王健
-
依托单位:
PET活体研究心肌乏氧状态与间充质干细胞治疗
-
批准号:30870725
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2008
-
负责人:朱朝晖
-
依托单位:
HIF-1α和SDF-1α/CXCR4在调控神经元前体细胞迁移中的作用研究
-
批准号:30800319
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2008
-
负责人:谭新杰
-
依托单位: